SMARCA4: Current status and future perspectives in non-small-cell lung cancer

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies

(2022) Antonio Passaro et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

(2022) Aaron C. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Immunotherapy for Non–Small-Cell Lung Cancer

(2022) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy

(2022) Yan Zhu et al.   CANCER BIOLOGY & THERAPY

Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors

(2022) Justine Gantzer et al.   ONCOLOGIST

Deciphering the tumor cell-infiltrating landscapes reveal microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC

(2022) Hao Chen et al.   JCI Insight

MiR-199a-5p-containing macrophage-derived extracellular vesicles inhibit SMARCA4 and alleviate atherosclerosis by reducing endothelial cell pyroptosis

(2022) Weijie Liang et al.   CELL BIOLOGY AND TOXICOLOGY

Clinically-meaningful improvements in therapy for unresectable NSCLC

(2022) Seigo Katakura et al.   Expert Review of Anticancer Therapy

cBAF complex components and MYC cooperate early in CD8+ T cell fate

(2022) Ao Guo et al.   NATURE

Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors

(2021) Kyriakos Chatzopoulos et al.   VIRCHOWS ARCHIV

Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189

(2021) D. Rodríguez-Abreu et al.   ANNALS OF ONCOLOGY

SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas

(2021) Jasna Metovic et al.   Journal of Thoracic Oncology

Targeting ARID1A Mutations in Cancer

(2021) Jaren Mullen et al.   CANCER TREATMENT REVIEWS

Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma

(2021) Hayato Kawachi et al.   Immunotherapy

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non–Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407

(2021) Steven F. Powell et al.   Journal of Thoracic Oncology

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition

(2021) Joao V. Alessi et al.   Journal of Thoracic Oncology

Recent updates in thoracic SMARCA4-deficient undifferentiated tumor

(2021) Aruna Nambirajan et al.   SEMINARS IN DIAGNOSTIC PATHOLOGY

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer

(2021) Guangsheng Zhu et al.   Frontiers in Immunology

PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells

(2021) Iga Jancewicz et al.   Cancers

STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?

(2021) Alessandro Di Federico et al.   EUROPEAN JOURNAL OF CANCER

SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy

(2021) Kristina Mardinian et al.   MOLECULAR CANCER THERAPEUTICS

Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung

(2021) Carla P. Concepcion et al.   Cancer Discovery

A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers

(2021) Ling Peng et al.   Frontiers in Immunology

Clinicopathologic Characteristics of BRG1-Deficient NSCLC

(2020) Ibiayi Dagogo-Jack et al.   Journal of Thoracic Oncology

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Marina C Garassino et al.   LANCET ONCOLOGY

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

(2020) Ryosuke Okamura et al.   Journal for ImmunoTherapy of Cancer

Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines

(2020) Marc Tischkowitz et al.   CLINICAL CANCER RESEARCH

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic driver genes and tumor microenvironment determine the type of liver cancer

(2020) Gang Wang et al.   Cell Death & Disease

Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors

(2020) Sarah Abou Alaiwi et al.   Cancer Immunology Research

BRG1 loss predisposes lung cancers to replicative stress and ATR dependency

(2020) Manav Gupta et al.   CANCER RESEARCH

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

(2020) Adam J Schoenfeld et al.   CLINICAL CANCER RESEARCH

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

(2020) Nadia Howlader et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond SMARCA4 Mutations: A Comprehensive Genomic Analysis

(2020) Aurélie Auguste et al.   Cells

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

(2020) D. Marinelli et al.   ANNALS OF ONCOLOGY

Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non–Small Cell Lung Carcinoma

(2020) Shujie Song et al.   MOLECULAR CANCER RESEARCH

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies

(2020) Richard C. Centore et al.   TRENDS IN GENETICS

SMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis

(2020) Liang Liu et al.   Molecular Oncology

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

(2020) Sreya Bagchi et al.   Annual Review of Pathology-Mechanisms of Disease

PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab

(2020) Haiyong Wang et al.   LUNG CANCER

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib

(2020) Yanhong Shang et al.   Scientific Reports

A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma

(2020) Gregory D. Jones et al.   JAMA Surgery

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

(2019) Linnéa La Fleur et al.   LUNG CANCER

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary

(2019) Yibo Xue et al.   Nature Communications

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

(2019) Yibo Xue et al.   Nature Communications

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

(2019) Deborah B Doroshow et al.   CLINICAL CANCER RESEARCH

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report

(2019) Tomoyuki Naito et al.   Thoracic Cancer

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

(2019) William Farnaby et al.   Nature Chemical Biology

Mechanisms of immunotherapy resistance: lessons from glioblastoma

(2019) Christopher M. Jackson et al.   NATURE IMMUNOLOGY

SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature

(2019) Brian D. Stewart et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report

(2019) Kohichi Takada et al.   Thoracic Cancer

Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden

(2019) Tomoyuki Naito et al.   LUNG CANCER

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade

(2018) Petar Jelinic et al.   JNCI-Journal of the National Cancer Institute

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

(2018) Jennifer R. Molina et al.   NATURE MEDICINE

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

(2018) Yonathan Lissanu Deribe et al.   NATURE MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

(2018) Deng Pan et al.   SCIENCE

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

(2018) Diana Miao et al.   SCIENCE

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade

(2018) Petar Jelinic et al.   JNCI-Journal of the National Cancer Institute

Induction of innate immune memory via microRNA targeting of chromatin remodelling factors

(2018) John J. Seeley et al.   NATURE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers

(2018) Florencia Rago et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer

(2018) Jingqin Lan et al.   CANCER RESEARCH

Targeting of BRM sensitizes BRG1 mutant lung cancer cell lines to radiotherapy

(2018) Erika Zernickel et al.   MOLECULAR CANCER THERAPEUTICS

Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities

(2017) Akihiko Yoshida et al.   MODERN PATHOLOGY

Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers

(2017) H. Courtney Hodges et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors

(2017) Thomas Januario et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg/CK7pos/HepPar-1pos immunophenotype

(2017) Abbas Agaimy et al.   VIRCHOWS ARCHIV

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers

(2017) Vural Tagal et al.   Nature Communications

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers

(2017) H. Courtney Hodges et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

First-Line Systemic Therapy Practice Patterns and Concordance With NCCN Guidelines for Patients Diagnosed With Metastatic NSCLC Treated at NCCN Institutions

(2017) Carrie Zornosa et al.   Journal of the National Comprehensive Cancer Network

PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease

(2016) Cigall Kadoch et al.   BIOCHEMISTRY

Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin

(2016) Benjamin Z Stanton et al.   NATURE GENETICS

ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice

(2016) Radhika Mathur et al.   NATURE GENETICS

SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development

(2016) X Shi et al.   ONCOGENE

The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation

(2016) Zhi-Yan Han et al.   Nature Communications

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

(2015) Bhavatarini Vangamudi et al.   CANCER RESEARCH

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer

(2015) E. H. Bell et al.   CLINICAL CANCER RESEARCH

Genomic Characterization of Non–Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing

(2015) Luiz H. Araujo et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type

(2015) Anthony N Karnezis et al.   JOURNAL OF PATHOLOGY

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

(2015) Marwan Kwok et al.   LANCET

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

(2015) Christine M. Fillmore et al.   NATURE

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

(2015) Francois Le Loarer et al.   NATURE GENETICS

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

(2015) Fiona K. Middleton et al.   Oncotarget

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

(2015) Frank P. Vendetti et al.   Oncotarget

Vulnerabilities of Mutant SWI/SNF Complexes in Cancer

(2014) Katherine C. Helming et al.   CANCER CELL

BRG1/SMARCA4 Inactivation Promotes Non-Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization

(2014) T. Orvis et al.   CANCER RESEARCH

Expression inactivation of SMARCA4 by microRNAs in lung tumors

(2014) Isabel F. Coira et al.   HUMAN MOLECULAR GENETICS

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation

(2014) B. G. Wilson et al.   MOLECULAR AND CELLULAR BIOLOGY

Recurrent SMARCA4 mutations in small cell carcinoma of the ovary

(2014) Petar Jelinic et al.   NATURE GENETICS

ARID1B is a specific vulnerability in ARID1A-mutant cancers

(2014) Katherine C Helming et al.   NATURE MEDICINE

SMARCA4 mutated in SCCOHT

(2014) Alessia Errico   Nature Reviews Clinical Oncology

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

(2014) G. R. Hoffman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1

(2013) T. Oike et al.   CANCER RESEARCH

Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma

(2013) Cigall Kadoch et al.   CELL

Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer--Mechanisms and Potential Therapeutic Insights

(2013) X. Wang et al.   CLINICAL CANCER RESEARCH

BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling

(2013) Barbara H Chaiyachati et al.   EMBO JOURNAL

Inactivating Mutations in SWI/SNF Chromatin Remodeling Genes in Human Cancer

(2013) Takahiro Oike et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy

(2013) Cigall Kadoch et al.   NATURE GENETICS

The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers

(2013) A. Hunter Shain et al.   PLoS One

Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features

(2012) Daisuke Matsubara et al.   CANCER SCIENCE

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

An essential role for a mammalian SWI/SNF chromatin-remodeling complex during male meiosis

(2012) Y. Kim et al.   DEVELOPMENT

The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer

(2012) Octavio A. Romero et al.   EMBO Molecular Medicine

Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity

(2012) Anbarasi Kothandapani et al.   EXPERIMENTAL CELL RESEARCH

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

(2012) Trevor J. Pugh et al.   NATURE

The genetic landscape of mutations in Burkitt lymphoma

(2012) Cassandra Love et al.   NATURE GENETICS

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint

(2010) Han Liu et al.   NATURE

The Biology of Chromatin Remodeling Complexes

(2009) Cedric R. Clapier et al.   Annual Review of Biochemistry

The SWI/SNF Chromatin Remodeling Complex Regulates Myocardin-Induced Smooth Muscle–Specific Gene Expression

(2009) Jiliang Zhou et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer

(2009) S. Rodriguez-Nieto et al.   CARCINOGENESIS

Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma

(2009) B Keenen et al.   ONCOGENE

The SWI/SNF complex and cancer

(2009) D Reisman et al.   ONCOGENE

Manipulation of SMARCA2 and SMARCA4 transcript levels in porcine embryos differentially alters development and expression of SMARCA1, SOX2, NANOG, and EIF1

(2008) Luca Magnani et al.   REPRODUCTION